Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non<b>-</b>Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO<sub>2</sub>TECT Randomized Clinical Trial of ESA-Treated Patients.

Kidney Med · 2023 · PMC10329165 · PMID 37427292

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

marginally significantP = 0.07so close (0.05 < p ≤ 0.1)

The P value for the interaction between the assigned study treatment and geographical region was marginally significant ( P = 0.07).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.